Blockchain Registration Transaction Record

GeoVax's Gedeptin Platform Aims to Overcome Cold Tumor Resistance in Immunotherapy

GeoVax Labs highlights Gedeptin platform as a complement to checkpoint inhibitors, targeting cold tumors resistant to immunotherapy. Learn about the JCI Insight study and planned neoadjuvant trial in head and neck cancer.

This news matters because it addresses a fundamental challenge in cancer immunotherapy: many tumors do not respond to checkpoint inhibitors due to a lack of immune activation. Gedeptin's ability to convert 'cold' tumors into 'hot' ones could expand the number of patients who benefit from existing immunotherapies like PD-1 inhibitors, potentially improving outcomes for millions with solid tumors. For patients with head and neck cancer and other resistant cancers, this approach offers hope for more effective combination treatments, reducing the burden of disease and improving survival rates.